P O'CONNOR

Summary

Affiliation: St. Michael's Hospital
Country: Canada

Publications

  1. doi request reprint Disease-modifying agents in multiple sclerosis
    Paul W O'Connor
    Multiple Sclerosis Clinic, St Michael s Hospital, Toronto, Canada Electronic address
    Handb Clin Neurol 122:465-501. 2014
  2. doi request reprint Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis
    P W O'Connor
    St Michael s Hospital, Toronto, Ontario, Canada
    Neurology 76:1858-65. 2011
  3. doi request reprint 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study
    Paul O'Connor
    St Michael s Hospital, Toronto, Canada
    Lancet Neurol 8:889-97. 2009
  4. doi request reprint Efficacy of intramuscular interferon beta-1a in patients with clinically isolated syndrome: analysis of subgroups based on new risk criteria
    P O'CONNOR
    St Michael s Hospital, Toronto, ON, Canada
    Mult Scler 15:728-34. 2009
  5. doi request reprint Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study
    P O'CONNOR
    St Michael s Hospital, Toronto, ON, Canada
    Neurology 72:73-9. 2009
  6. ncbi request reprint Natalizumab and the role of alpha 4-integrin antagonism in the treatment of multiple sclerosis
    Paul O'Connor
    St Michael s Hospital, Division of Neurology, 30 Bond Street, Suite 3 007 Shuter Wing, University of Toronto, Toronto, Ontario, M5B 1W8, Canada
    Expert Opin Biol Ther 7:123-36. 2007
  7. ncbi request reprint A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses
    P W O'Connor
    University of Toronto, Ontario, Canada
    Neurology 66:894-900. 2006
  8. ncbi request reprint The effects of intramuscular interferon beta-Ia in patients at high risk for development of multiple sclerosis: a post hoc analysis of data from CHAMPS
    Paul O'Connor
    Division of Neurology, St Michael s Hospital, University of Toronto, Toronto, Ontario, Canada
    Clin Ther 25:2865-74. 2003
  9. ncbi request reprint Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis
    Paul O'Connor
    Division of Neurology, St Michael s Hospital, 30 Bond Street, Suite 3007S Shuter Wing, Toronto, Ontario, Canada
    Mult Scler 11:568-72. 2005
  10. ncbi request reprint Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects
    P W O'Connor
    St Michael s Hospital, Toronto, Ontario, Canada
    Neurology 62:2038-43. 2004

Detail Information

Publications21

  1. doi request reprint Disease-modifying agents in multiple sclerosis
    Paul W O'Connor
    Multiple Sclerosis Clinic, St Michael s Hospital, Toronto, Canada Electronic address
    Handb Clin Neurol 122:465-501. 2014
    ..This chapter will consider the efficacy and safety of both established and investigational agents for the treatment of MS. ..
  2. doi request reprint Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis
    P W O'Connor
    St Michael s Hospital, Toronto, Ontario, Canada
    Neurology 76:1858-65. 2011
    ....
  3. doi request reprint 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study
    Paul O'Connor
    St Michael s Hospital, Toronto, Canada
    Lancet Neurol 8:889-97. 2009
    ....
  4. doi request reprint Efficacy of intramuscular interferon beta-1a in patients with clinically isolated syndrome: analysis of subgroups based on new risk criteria
    P O'CONNOR
    St Michael s Hospital, Toronto, ON, Canada
    Mult Scler 15:728-34. 2009
    ..0007, P = 0.0405) and patients with at least nine T2 lesions at baseline (P = 0.0044). These data confirm that IM IFNbeta-1a delays conversion to CDMS in patients with CIS...
  5. doi request reprint Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study
    P O'CONNOR
    St Michael s Hospital, Toronto, ON, Canada
    Neurology 72:73-9. 2009
    ..To report the results of a 24-month extension of a phase II trial assessing the efficacy, safety, and tolerability of the once-daily oral sphingosine-1-phosphate receptor modulator, fingolimod (FTY720), in relapsing multiple sclerosis (MS)...
  6. ncbi request reprint Natalizumab and the role of alpha 4-integrin antagonism in the treatment of multiple sclerosis
    Paul O'Connor
    St Michael s Hospital, Division of Neurology, 30 Bond Street, Suite 3 007 Shuter Wing, University of Toronto, Toronto, Ontario, M5B 1W8, Canada
    Expert Opin Biol Ther 7:123-36. 2007
    ....
  7. ncbi request reprint A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses
    P W O'Connor
    University of Toronto, Ontario, Canada
    Neurology 66:894-900. 2006
    ..In this randomized, double-blind, placebo-controlled Phase II study, the authors examined the safety and efficacy of oral teriflunomide in multiple sclerosis (MS) with relapses...
  8. ncbi request reprint The effects of intramuscular interferon beta-Ia in patients at high risk for development of multiple sclerosis: a post hoc analysis of data from CHAMPS
    Paul O'Connor
    Division of Neurology, St Michael s Hospital, University of Toronto, Toronto, Ontario, Canada
    Clin Ther 25:2865-74. 2003
    ....
  9. ncbi request reprint Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis
    Paul O'Connor
    Division of Neurology, St Michael s Hospital, 30 Bond Street, Suite 3007S Shuter Wing, Toronto, Ontario, Canada
    Mult Scler 11:568-72. 2005
    ..In a six month, phase II clinical trial of patients with relapsing MS, natalizumab significantly reduced the formation of new gadolinium-enhanced (Gd+) lesions and the number of clinical relapses...
  10. ncbi request reprint Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects
    P W O'Connor
    St Michael s Hospital, Toronto, Ontario, Canada
    Neurology 62:2038-43. 2004
    ..Natalizumab (Antegren) is a humanized anti-alpha4-integrin antibody that inhibits the trafficking of leukocytes across endothelium by blocking binding of alpha4beta1-integrin to vascular cell adhesion molecule-1...
  11. doi request reprint Robust perfusion deficits in cognitively impaired patients with secondary-progressive multiple sclerosis
    P L Francis
    Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
    AJNR Am J Neuroradiol 34:62-7. 2013
    ..Cognitive impairment is a common, disabling symptom of MS. We investigated the impact of cerebral perfusion and brain and lesion volumetry on cognitive performance in 45 patients with SPMS by using MR imaging...
  12. ncbi request reprint Randomized study of once-weekly interferon beta-1la therapy in relapsing multiple sclerosis: three-year data from the OWIMS study
    M S Freedman
    Ottawa Hospital General Campus, Ottawa, Ontario, Canada
    Mult Scler 11:41-5. 2005
    ..Objective: An OWIMS extension permitted assessment of longer-term efficacy/safety of qw IFN beta-1a in relapsing-remitting multiple sclerosis (RRMS)...
  13. doi request reprint A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS
    M S Freedman
    University of Ottawa, Ottawa Hospital Research Institute, 501 Smyth Road, Ottawa, Ontario, Canada
    Neurology 77:1551-60. 2011
    ..To evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis (SPMS) who express human leukocyte antigen (HLA) haplotype DR2 or DR4 (DR2(+) or DR4(+))...
  14. doi request reprint Randomized trial of oral teriflunomide for relapsing multiple sclerosis
    Paul O'Connor
    University of Toronto, Toronto, ON, Canada
    N Engl J Med 365:1293-303. 2011
    ..Teriflunomide is a new oral disease-modifying therapy for relapsing forms of multiple sclerosis...
  15. ncbi request reprint A rapid ELISA-based serum assay for myelin basic protein in multiple sclerosis
    A J Chamczuk
    Structural Biology and Biochemistry, Research Institute, The Hospital for Sick Children, Toronto, ON, Canada M5G 1X8
    J Immunol Methods 262:21-7. 2002
    ..The success of the assay is dependent on the use of heparin, an anionic molecule, which neutralizes the positive charge on the highly cationic MBP...
  16. doi request reprint Decreased frontal lobe gray matter perfusion in cognitively impaired patients with secondary-progressive multiple sclerosis detected by the bookend technique
    R I Aviv
    Department of Medical Imaging, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
    AJNR Am J Neuroradiol 33:1779-85. 2012
    ..We sought to quantify differences in MR imaging-based bookend-derived cerebral perfusion between cognitively impaired and nonimpaired patients with SPMS...
  17. ncbi request reprint Multiple sclerosis fatigue is associated with reduced psychomotor vigilance
    D Rotstein
    Division of Neurology, Department of Medicine, University of Toronto, Canada
    Can J Neurol Sci 39:180-4. 2012
    ..Fatigue is common and disabling in multiple sclerosis, yet its physiologic substrates remain poorly defined. The aim of this study was to determine the relationship between fatigue and an objective measure of alertness in MS patients...
  18. pmc APOE epsilon4 and the cognitive genetics of multiple sclerosis
    O Ghaffar
    Neuropsychiatry Program, Department of Psychiatry, Sunnybrook Health Sciences Centre, FG08 2075 Bayview Avenue, Toronto, ON M4N 3M5, Canada
    Neurology 74:1611-8. 2010
    ..The purpose of this study was to determine whether the epsilon4 allele of APOE is associated with cognitive deficits in patients with MS...
  19. pmc A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis
    J M Burton
    Division of Neurology, St Michael s Hospital, Toronto, Canada
    Neurology 74:1852-9. 2010
    ..Our aim was to assess the tolerability of high-dose oral vitamin D and its impact on biochemical, immunologic, and clinical outcomes in patients with MS prospectively...
  20. doi request reprint Diffusion tensor imaging abnormalities in depressed multiple sclerosis patients
    A Feinstein
    Department of Psychiatry, University of Toronto, Toronto, Canada
    Mult Scler 16:189-96. 2010
    ....
  21. ncbi request reprint Age at onset of multiple sclerosis may be influenced by place of residence during childhood rather than ancestry
    J Kennedy
    The Hospital for Sick Children, University of Toronto, Toronto, Ont L5M 4A7, Canada
    Neuroepidemiology 26:162-7. 2006
    ....